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Summary
Background: Endothelial dysfunction has been implicated in the pathophysiology of cardiovascular dis-
eases, including arterial hypertension. The present study was undertaken to assess endothelial
function in postmenopausal women with arterial hypertension receiving hormone replace-
ment therapy and antihypertensive treatment.
Material/Methods: A group of 76 women with natural menopause and essential mild to moderate arterial hyper-
tension entered the study. Forty women received a transdermal, combined hormone replace-
ment therapy (HRT) of 17β-estradiol and norethisterone acetate, whereas 36 served as con-
trols. At baseline and at 3 and 12 months, all patients underwent 24-hr blood pressure moni-
toring and an exercise test, before which, at peak exercise, and after a 15-min recovery period
venous blood was drawn to measure the level of nitrite/nitrate (NOx) according to the Griess
method.
Results: At 3 and 12 months after beginning HRT, the level of NOx at rest was slightly increased, with
marked individual differences in response to HRT. In women not receiving HRT, NOx did
not change. In the HRT group, 52.5% at 3 months and 47.5% at 12 months had significantly
increased levels compared with the baseline values (17.8±6.7 vs. 32.8±4.5 vs. 28.7±1.1
µmol/l; p=0.002). The increased NOx level in responders was associated with decreased LDL
cholesterol (3.62±1.2 vs. 3.53±1.3 vs. 2.6±0.6 mmol/l; p=0.01). At 12 months, blood pressure
values did not differ from those at baseline in either group.
Conclusions: The significant increase of NOx in half of the women receiving HRT suggests that only
responders experience the cardioprotective effects of HRT.
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BACKGROUND
Arterial hypertension is one of the major coronary risk
factors for increasing morbidity and mortality from car-
diovascular diseases and stroke. While most studies of
hypertension have focused on men, women also experi-
ence significant hypertension-related morbidity and
mortality. However, the incidence of hypertension and
cardiovascular disease is significantly lower in women
than in men until the onset of menopause, at which
time cardiovascular incidence increases dramatically in
women and eventually approaches that of men [1].
These observations indicate that estrogen loss con-
tributes to the menopause-related increase in blood
pressure and cardiovascular disease and suggest that
the use of hormone replacement therapy could decrease
cardiovascular disease in postmenopausal women.
However, new findings from the Women’s Health
Initiative study [2] suggest that estrogen therapy has
few positive benefits and some significant negative
effects on the health of postmenopausal women.
Conversely, some clinical and basic research studies
indicate that estrogen replacement therapy beneficially
reduces blood pressure [3]. Estrogens have been sug-
gested to exert vasoprotective effects as they influence
the renin angiotensin system, have antioxidant proper-
ties, and may act as calcium-blocking agents [4,5]. Thus,
HRT would be expected to leave blood pressure
unchanged or to actually promote a blood pressure
reduction in postmenopausal hypertensive and nor-
motensive women. Nevertheless, the use of hormone
replacement therapy in hypertensive women remains a
controversial issue. Caution is recommended, as the
effect of the therapy on blood pressure is equivocal.
Endothelial dysfunction has been implicated in the
pathophysiology of cardiovascular diseases, including
arterial hypertension, atherosclerosis, hypercholes-
terolemia, coronary artery disease, and heart failure.
Endothelial function has been shown to deteriorate with
age in both sexes. However, the accumulating data indi-
cate that age-related changes in women are more pro-
nounced with loss of ovarian function, which strongly
suggests a relationship with sex hormones and their
influence on vascular endothelial function. This has
been confirmed by experimental [6] and clinical studies
demonstrating abnormal vasodilatation in women after
surgical and natural menopause [4–8], especially in the
presence of atherosclerotic risk factors [9].
Endothelial dysfunction is an imbalance among
endothelium-derived factors in favor of vasoconstrictive,
pro-atherogenic substances over vasodilative ones [10].
Nitric oxide is an important anti-atherogenic factor, and
reduced nitric oxide availability has been suggested to
serve as a hallmark of endothelium dysfunction. In
experimental studies, a strong relation between hyper-
tension and endothelial cell morphological and func-
tional alteration has been confirmed [10]. In post-
menopausal women receiving estrogen replacement
therapy (ERT), nitric oxide returns to a level compara-
ble to its physiological level in women before meno-
pause [11]. This is associated with improved endothelial
function, which may be immediate [12] or after long-
term treatment [13,14]. The available experimental and
clinical studies on the effect of estrogen replacement
therapy on the metabolism of nitric oxide are limited to
postmenopausal women with normal blood pressure.
Taking into account the complex relations between
endothelial function, menopause, and hypertension, we
focused on the role of endothelium dysfunction in
hypertensive postmenopausal women and its possible
restoration through the use of hormone replacement
therapy combined with antihypertensive treatment. The
present study was undertaken to assess the influence of
combined transdermal hormone replacement therapy
on blood pressure and endothelial function in post-
menopausal women with arterial hypertension receiving
antihypertensive treatment.
MATERIAL AND METHODS
The study was designed for women treated at the
Outpatient Unit of the 1st Cardiac Department, Jagiel-
lonian University Medical College. A group of 76 women
(mean age: 52.5±5.8 years) with natural menopause and
essential mild to moderate arterial hypertension with a
duration of 5.9±5.0 years entered the study. The mean
time of amenorrhea was 54.2±47.4 months, FSH was
>21 U/l (mean: 74.6±27.1), and estradiol <50 pg/ml
(mean 17.3±9.5). Subjects with coronary artery disease,
heart failure, diabetes, obesity, coagulation disorders,
liver damage, hyperlipidemia, or imminent neoplastic
process were excluded from the study. None of the
patients had received hormone replacement therapy
before. Hypotensive treatment consisted of beta block-
ers, calcium antagonists, diuretics, and angiotensin-con-
verting enzyme inhibitors. The type and dosages of the
antihypertensive agents remained unaltered during the
12-month follow-up. None of the patients received lipid-
lowering treatment.
After gynecological examination, women with a low
level of hormones and/or severe postmenopausal symp-
toms were offered transdermal hormone substitution
with 17β-estradiol and norethisterone acetate (Estra-
comb TTS 50, Novartis). The forty women who accept-
ed the treatment received hormone replacement thera-
py, whereas the 36 women who chose not to take HRT
did not receive the treatment. All patients underwent
cytology of the vaginal epithelium as well as ultrasound
examination, mammography and densitometry. The
enrolled women had the basic measurements taken in a
clinical setting: sedimentation rate, blood morphology,
general urinary test, proteins, creatinine, total bilirubin,
transaminase, serum alkaline phosphatase, and coagula-
tion parameters (INR, APTT). Each patient underwent
a physical examination.
The study protocol was approved by the Jagiellonian
University Ethics Committee. The enrolled patients
were informed about the aim of the study and gave
their written consent.
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24-hr non-invasive ambulatory blood-pressure
monitoring (ABPM)
At baseline and at 3 and 12 months, all patients under-
went 24-hr ABPM using a SpaceLabs 90207 oscillomet-
ric recorder (SpaceLabs Inc, Redmond, Washington,
USA) with recordings every 20 min during the day
(6.00–22.00) and every 30 min at night (22.00–6.00).
Day and night time intervals were defined arbitrarily for
all patients because of the identical hospital regime. The
recorder was mounted between 8.00 and 9.00 a.m.
We measured systolic and diastolic blood pressure sepa-
rately over the entire 24 hours and at night the noctur-
nal systolic and diastolic blood pressure drop. We ana-
lyzed blood pressure variability from the standard devi-
ations of all the blood pressure measurements taken
over the entire 24 hours.
Biochemical tests
At baseline and at 3 and 12 months all patients under-
went an exercise stress test according to Bruce’s proto-
col. Before, at peak exercise, and after a 15-min recov-
ery period, venous blood was drawn to measure the
level of nitrite/nitrate (NOx). The level of endogenous
nitric oxide was determined from the measurement of
nitrite/nitrate (NOx) concentration in venous blood with
the modified Griess method using NADPH reductase
[15].
At baseline and at 3 and 12 months we measured total
cholesterol, HDL and LDL cholesterol, and triglyc-
erides. Total cholesterol and triglycerides were mea-
sured with the enzymatic-colorimetric method using
CHOD-PAP Boehringer Mannheim kits on RA 1000.
HDL cholesterol was measured after precipitation of
lipid fractions with heparin and MN2+. LDL cholesterol
was calculated according to the Friedewald formula.
FSH and estradiol were measured using the MEIA kits
of Abbott (sensitivity for estradiol 1 ng/ml, for FSH 0.5
mIU/ml) at the same time intervals as the remaining
biochemical parameters.
The biochemical tests were performed at the Depart-
ment of Clinical Biochemistry, Chair of Clinical Bioche-
mistry and Diagnosis, Jagiellonian University Medical
College.
Statistical analysis
Statistical analysis was done using Statistica 5.0 PL for
Windows. Basic statistics such as means, standard devia-
tions, and the normal distribution were analyzed. Inter-
group differences were tested using the chi-square test,
Student’s t-test and one-way variance analysis. Only
two-sided tests were used. A p<0.5 was considered as
statistically significant.
RESULTS
Table 1 summarizes the anthropometric parameters
and blood pressure values in the study population and
HRT – hormone replacement therapy, BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, NS – not significant
HRT Group 1 Without HRT Group 2 p
Age [years]
BMI [kg/m2]
WHR
Duration of hypertension [years]
SBP [mmHg]
DBP [mmHg]
24 h SBP/DBP [mmHg]
Day-time SBP/DBP [mmHg]
Night-time SBP/DBP [mmHg]
Total cholesterol [mmol/l]
LDL cholesterol [mmol/l]
HDL cholesterol [mmol/l]
TG [mmol/l]
52.8±5.3
28.3±4.8
0.87±0.06
5.8±4.1
143.1±19.9
89.5±6.4
128.7±16.3 / 85.3±8.0
133.4±17.4 / 89.5±8.4
119.4±16.2 / 77.1±9.7
6.1±1.2
3.9±1.0
1.5±0.4
1.8±0.7
53.6±5.9
27.0±3.6
0.86±0.08
6.6±4.5
141.8±16.8
90.6±7.9
130.3±12.7 / 84.7±9.1
133.8±12.6 / 88.4±8.3
123.5±14.6/77.5±10.9
6.4±1.1
4.0±1.1
1.5±0.3
2.0±0.7
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Table 1. Characteristics of study groups: Group 1 – hypertensive women receiving hormone replacement therapy, Group 2 - hypertensive women
without hormone replacement therapy.
HRT
Group 1
Regimen
Antihypertensive Drug Used (monotherapy or in combination)
Without HRT
Group 2
Single drug therapy, %
Two antihypertensive drugs, %
Three antihypertensive drugs, %
Four antihypertensive drugs, %
ACE Inhibitor %
Calcium antagonist %
Beta-blocker %
Thiazide diuretic %
Others %
53
41
3
3
53.3
10.0
60.0
43.3
2.7
46.6
3.3
73.3
26.6
3.3
42
53
5
0
Table 2. Antihypertensive treatment in the two studied groups:
Group 1: hypertensive women receiving HRT and
Group 2: hypertensive women not receiving hormone
replacement therapy.
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Table 2 contains data on the antihypertensive treat-
ment. At baseline the study groups did not differ in age,
BMI, waist/hip ratio, duration of hypertension, and
blood pressure (Table 1).
Blood pressure
At 3 months, women receiving hormone replacement
therapy showed a tendency towards lower systolic and
diastolic blood pressure. At 12 months, blood pressure
values did not differ from those at baseline in either
group (Table 3). In women without HRT, blood pres-
sure remained unaltered.
Endothelial function parameters
At 3 and 12 months after hormone replacement therapy,
the level of nitrite/nitrate at rest was slightly increased,
with marked individual differences in response to HRT
(23.6±11.7 vs. 28.7±19.9 vs. 26.2±17.4 umol/l, NS). In
women not receiving HRT, nitrite/nitrate did not change
significantly during the 12 months of follow-up
(24.8±11.7 vs. 25.1±14.7 vs. 21.6±13.2 µmol/l, NS).
In the HRT group, 21 women (52.5%) at 3 months and
19 (47.5%) at 12 months had significantly increased levels
of NOx compared with the baseline values (Table 4). The
increased NOx level in responders was associated with
decreased LDL cholesterol. The level of circulating estra-
diol was similar in women with and without increased
NOx (216±56 vs. 207±64 pg/ml; NS) (Table 5).
DISCUSSION
In the present study, postmenopausal women with mild
to moderate arterial hypertension receiving antihyper-
tensive treatment and HRT showed a tendency towards
lower blood pressure at 3 months and a return to base-
line values at 12 months. These findings are in accor-
dance with the results of Lip et al. [16], who, in a prospe-
ctive open study in women receiving antihypertensive
treatment together with HRT, did not find significant dif-
ferences in blood pressure. Similarly, the study of
Sumino et al. [17] demonstrated that hormone replace-
At baseline At 3 months At 12 months p
Responders n=21
Non-responders n=19
NOx [mmol/l] 
LDL [mmol/l]
NOx [mmol/l] 
LDL [mmol/l]
17.8±6.7
3.62±1.2
22.8±8.6
4.1±1.7
32.8±14.5
3.3±1.3
24.7±13.7
3.53±1.3
28.7±15.5
2.6±0.6
20.0±9.7
3.66±1.1
0.002
0.01
NS
NS
Table 4. Nitrite/nitrate (NOx) and LDL cholesterol levels at baseline and at 3 and 12 months in women receiving hormone replacement therapy,
divided into responders and non-responders.
HRT Group 1
Three months
Tvelve months
Without HRT Group 2 95 % CI for differences betweengroups
D 24-h SBP [mmHg]
D 24-h DBP
D day-time SBP [mmHg]
D day-time DBP
D night-time SBP [mmHg]
D night-time DBP
D 24-h SBP [mmHg]
D 24-h DBP
D day-time SBP [mmHg]
D day-time DBP
D night-time SBP [mmHg]
D night-time DBP
–2.5 (–13.8 to 8.8)
–3.2 (9.4 to 2.8)
–5.2 (–17.8 to 7.4)
–4.7 (–10.8 to 1.5)
1.4 (–11.8 to 14.7)
–1.4 (–9.4 to 6.7)
0.3 (–7.1 to 7.8)
–0.7 (–5.9 to 4.4 )
–1.0 (–9.2 to 7.2)
–1.2 (–6.8 to 4.4)
2.7 (–4.1 to 9.6)
–0.2 (–5.1 to 4.4)
–1.2 (–5.0 to 2.6)
–1.1 (–3.6 to 1.3)
–1.8 (–6.3 to 2.6)
–1.4 (–4.2 to 1.3)
–1.5 (–5.8 to 2.8)
–0.8 (–3.6 to 2.0)
–0.3 (–5.1 to 4.4)
0.1 (–3.1 to 3.3)
–0.8 (–65.1 to 4.4)
–0.4 (–3.9 to 3.0)
0.8 (–3.7 to 5.3)
1.1 (–2.1 to 4.2)
(–12.0 to 9.4)
(–8.1to 3.9)
(–15.5 to 8.7)
(–9.5 to 2.9)
(–9.7 to 15.5)
(–8.3 to 7.1)
(–8.2 to 8.2)
(–6.26 to 5.06)
(–9.2 to 8.8)
(–6.82 to 5.22)
(–5.79 to 9.59)
(–6.62 to 4.02)
Table 3. Changes from baseline of 24-hr ambulatory blood pressures in the group receiving hormone replacement therapy (HRT) and without
HRT – 3 and 12 months of follow-up (means (95 % CI)) and 95 % CI for differences between groups.
HRT
At baseline
At 3 months
At 12 months
Without HRT p
Estradiol [pg/ml]
FSH [U/l]
Estradiol [pg/ml]
FSH [U/l]
Estradiol [pg/ml]
FSH [U/l]
19.8±9.9
72.6±28.7
92.5±26.6*
46.7±24.2*
174.4±94.8*
20.5±8.9*
18.4±8.6
76.0±30.4
18.9±9.2
70.6±32.8
16.0±7.2
72.6±29.0
NS
NS
P<0.01
P<0.05
P<0.001
P<0.005
Table 5. Estradiol and FSH levels at baseline and at 3 and 12 months
in two groups: Group 1 – hypertensive women receiving
hormone replacement therapy and Group 2 – hypertensive
women without hormone replacement therapy.
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ment therapy does not affect blood pressure in hyperten-
sive postmenopausal women whose blood pressure has
been well controlled prior to the initiation of HRT.
Kornhauser et al. [18] conducted a randomized double-
blind study over 90 days in menopausal women with mild
to moderate hypertension. The 55 women first discontin-
ued their antihypertensive medication. The patients were
allocated to three groups: placebo, estradiol, and estradi-
ol plus progesterone analogue. Blood pressure decreased
in the placebo group and remained unchanged in the
other two groups [18]. In contrast, Manhem et al. [19]
tested the effects of transdermal estrogen on blood pres-
sure in a placebo-controlled, double-blind, cross-over
study which relied on 24-hr blood pressure monitoring.
Transdermal estrogen had a small blood pressure-lower-
ing effect on daytime blood pressure and did not inter-
fere with nocturnal blood pressure [19]. However, larger
trials with different primary end-points do not suggest
that HRT influences blood pressure to a significant
degree. The post-menopausal estrogen/progestin inter-
ventions (PEPI) trial focused on systolic blood pressure
among various end-points [20]. Patients were random-
ized to placebo or conjugated estrogens with or without
progestin, in a cyclic or consecutive fashion. No treat-
ment-related effects on systolic blood pressure were
observed. In the Heart and Estrogen/progestin Repla-
cement Study (HERS), blood pressure was documented
to be no different in the examined groups [21].
As blood pressure is determined by the interplay
between peripheral vascular resistance and volume reg-
ulatory mechanisms, the effects of HRT on vascular and
endothelial function should receive focused attention. It
is generally recognized that arterial hypertension
impairs endothelium-dependent vasodilation [22–24].
However, reports on the effect of essential hypertension
on plasma nitrite/nitrate levels are controversial.
Takayashi et al. [25] demonstrated that higher blood
pressure is associated with higher nitrite/nitrate levels.
Sagnella et al. [26] did not find any significant differ-
ences, whereas Node et al. [27] demonstrated lower
nitrite/nitrate levels in hypertensives compared with
controls. In the present study, at 3 and 12 months after
transdermal combined hormone replacement therapy
nitrite/nitrate levels were insignificantly increased with
marked individual variations in response to HRT. It is
noteworthy that only half of the women responded with
an increase in nitrite/nitrate levels after HRT.
The present finding confirms the division of women
receiving HRT into responders and nonresponders
observed by Imthurn et al. [28] in a group of 26 nor-
motensive postmenopausal women receiving oral com-
bined hormone replacement therapy for 12 months.
Similar to the present study, marked individual varia-
tions of NO2/NO3 in response to estrogen replacement
therapy were demonstrated by other investigators
[28–30]. The individual capability to restore estrogen
expression probably plays a role in this phenomenon
[31]. Before menopause, estrogen receptors are con-
stantly stimulated by estrogens, rapidly increasing nitric
oxide in response to increased estrogens in the blood
[32]. As estrogens up-regulate estrogen receptors [33],
the decreasing estrogens in women after menopause
gradually down-regulate estrogen receptors in vessels,
until their complete loss [31]. Women with endothelial
injury, as in arterial hypertension, may be not capable
of restoring estrogen receptors, and for this reason
nitric oxide levels may rise only slightly or not at all in
response to estrogens. The inability of nonresponders to
restore estrogen receptors may also play a role in pro-
ducing variable reactions to estrogen therapy [31].
Another reason for variations in NO response to hor-
mone replacement therapy is decreased LDL cholesterol
in responders, which inhibits nitric oxide synthase. In
the present study, NOx increase in response to HRT was
found only in those women in whom LDL cholesterol
was significantly lower. Although nitric oxide increases
mainly through estrogen receptors, the increased level of
nitrites/nitrates in postmenopausal women may be partly
due to decreased LDL cholesterol.
A negative effect of progesterone on estrogen-induced
nitric oxide increase cannot be excluded, either.
Progestagens have been found to blunt the cardiopro-
tective properties of estrogens [14,34] and aggravate
hypertension-related vascular injury [35]. Also in a
study by Imthurn et al. [28], plasma nitrites/nitrates did
not increase significantly when estrogens were com-
bined with medroxyprogesterone or cyproterone
acetate. These findings imply that progestagens, both
natural and synthetic, irrespective of whether they are
derivatives of testosterone or 17-OH progesterone,
attenuate estrogen-induced increase in NO production.
Progesterone probably inhibits estrogen-induced nitric
oxide generation [36]. However, the mechanism by
which progesterone decreases the estradiol-induced
increase in NO production is not well understood.
In contrast, Nabulsi et al. [37] demonstrated that a com-
bined HRT consisting of estrogens and medroxyproges-
terone shows better cardioprotection even when com-
pared with estrogens alone. Other investigators [28] also
observed marked increases of NO metabolites in blood
NOx at 6 months after combined HRT (transdermal
estradiol plus norethisterone) between the first and 12th
day of the menstrual cycle. They also found that a 12-
month combined HRT (oral estradiol plus cyproterone
acetate or medroxyprogesterone) results in a marked
increase of NOx in blood, and the addition of proges-
terone does not attenuate the effect of estrogens [28].
Best et al. [38] also demonstrated a marked increase of
NO metabolites in a small group of postmenopausal
women receiving a combined HRT for 6 months. In
their study, the level of NOx varied in response to estro-
gen therapy from subject to subject.
The marked increase of NO metabolites observed by the
above-mentioned investigators compared with the
increasing tendency in the present study may be
accounted for by a different route of administration and
type of hormone preparations. It should, however, be
remembered that the studies quoted above were carried
out in postmenopausal women with normal blood pres-
sure, whereas our results were obtained in post-
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menopausal women with mild to moderate arterial
hypertension.
The question arises whether the varying NO response
to HRT is related to varying estrogen levels in the
blood, which in turn are associated with irregular HRT
use. In order to exclude this possibility we measured
estrogen levels at the same time points as the nitri-
tes/nitrates.
In the present study, despite various NO responses to
estrogens in responders and nonresponders, the level of
circulating estradiol was similar in both groups. In con-
trast, Best et al. [38] demonstrated marked individual
variations by the end of the study. Other investigators
[28,36] did not measure the level of estradiol by the end
of their studies. For this reason it cannot be excluded
that the differences in the results obtained by other
investigators and in the present study are related to
varying levels of estrogens in the blood.
Methodological limitations
In the present study, endogenous generation of nitric
oxide was measured from the level of circulating
nitrites/nitrates. The question arises whether this
methodological approximation is appropriate. Nitric
oxide is a labile molecule which degrades to nitrites and
nitrates within several seconds after its formation.
Studies in vivo have confirmed that endogenous changes
in NO generation induced by endotoxins or L-methyl-
nitroarginine may be assessed from changes in the cir-
culating or excreted nitrites/nitrates [39–41]. Hibbs et
al. [41], using L-guanidine-arginine as a substrate for
nitric oxide synthesis, demonstrated that in humans
increased nitrate formation in the blood occurs due to
nitric oxide generated from labeled L-arginine.
Although these studies suggest that nitric oxide is the
primary source of circulating nitrites/nitrates, nitrates
encountered in food should also be taken into account.
However, it is rather improbable that changes in the cir-
culating nitrites/nitrates in the present studies should be
ascribed to diet. Firstly, nitrates in food are excreted in
the urine within 18 hours after their digestion [42]. In
the present study the level of nitrites/nitrates was mea-
sured at 14 hours after the last meal; therefore, most
nitrates had been eliminated by that time.
Node et al. [27] found that plasma NOx stabilizes 12
hours after the last meal. Secondly, because the patients
were their own controls, it can be assumed that dietary
habits were similar before and during HRT, thus elimi-
nating the effect of food nitrates. Thirdly, if the
endothelium is not the only site of NO generation,
changes in NO2/NO3 levels are not necessarily associated
with impaired endothelial function [43,44]. However,
the amount of nitric oxide released from blood platelets
is about 20 times smaller than endothelium-derived NO
[45], thus justifying the choice of methodology.
The inflammatory process has a potential effect on the
level of NOx. In our study, standard markers of the
inflammatory process or clinical symptoms of atheroscle-
rosis were not found; therefore, we may assume that
variations of NO2/NO3 reflect changes in NO generation.
A methodological limitation is also the antihypertensive
treatment in our study. As it is still unknown whether
hormone replacement therapy may modify the effects of
antihypertensive treatment, most of all whether it does
not attenuate the effects of hypotensive agents, and
whether antihypertensive treatment may alter the bene-
fits of HRT, the present study was designed to prospec-
tively study 76 postmenopausal women with pharmaco-
logically controlled arterial hypertension. The hypoten-
sive treatment was similar in both groups, i.e. receiving
and not receiving HRT, and it included all classes of anti-
hypertensive drugs (beta blockers, calcium antagonists,
diuretics, and ACE inhibitors). The doses of the drugs
were also similar in both groups and they remained unal-
tered throughout the 12 months. We may then assume
that the lack of need to increase the doses of antihyper-
tensive agents shows that HRT does not aggravate arteri-
al hypertension, which has not been indisputable in light
of elevated blood pressure when using contraceptives.
There is no doubt that all the parameters analyzed in the
present study, including endothelial function, vascular
structure and function, and lipid and carbohydrate
metabolism, are modifiable by antihypertensive treatment.
However, if we take into account the fact that at baseline
both groups were similar with respect to these parame-
ters, and hypotensive treatment was the same throughout
the follow-up, beneficial changes in the lipid profile are
due to HRT, indicating that hormones significantly con-
trol lipid metabolism, which attenuates endothelial injury
and inhibits atherosclerosis. This is reflected in the
increased NO generation in the vascular walls of patients
receiving hormone replacement therapy compared with
those who did not receive HRT. Varying endothelial
response with respect to NO formation also seems to be
unrelated to hypotensive treatment, because the same pat-
tern was observed in both responders and nonresponders.
The last possible limitation of this study is that it was not
designed as a double-blind, randomized, placebo-based
study. In addition, the number of subjects included in
the study was relatively small. Therefore, we cannot
exclude the possibility that there is a selection bias in the
results. Hence, our findings require further support in
larger, placebo-controlled studies.
To sum up, the combination of hormone replacement
therapy and antihypertensive treatment does not atten-
uate, and even may improve, the beneficial effects of
these agents.
CONCLUSIONS
One-year combined transdermal hormone replacement
therapy with estrogens and progestagens does not sig-
nificantly affect blood pressure values and variability in
postmenopausal women with arterial hypertension. The
significant increase of NOx in half of the women receiv-
ing HRT suggests that only responders experience the
cardioprotective effects of HRT.
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